Decision Resources, Inc., announces the publication of Type 2 Diabetes, a new study that evaluates the commercial potential of novel agents to treat this indication. This study presents data on investigational therapies in early- and late-stage development and offers critical strategic analysis to help companies competing in this market to position their products.

  (Photo:  )   Three Major Collaborations to Produce Inhalable Insulin 

The three major producers of insulin-Eli Lilly, Novo Nordisk, and Aventis (with Pfizer)-are all developing inhalable formulations of insulin with small company partners. Exubera, the dry powder insulin formulation developed by Inhale Therapeutic Systems in partnership with Pfizer and Aventis is expected to be the first to market. Aradigm's AERx inhaled insulin technology (in collaboration with Novo Nordisk), Dura Pharmaceuticals' (recently purchased by Elan) Spiros inhaler (in collaboration with Eli Lilly), and AeroGen's AeroDose system each offer unique advantages. Thought leaders believe that the convenience of inhalable insulin will lead to better patient compliance- particularly among children, the elderly, and those new to insulin therapy, although inhalable insulin not expected to replace injected insulin in the near future. Its price is likely to be significantly higher than that of injectable insulin, leading many third-party payers to restrict its use.

Amylin Pharmaceuticals, Novo Nordisk, and Novartis Developing Promising Agents

Glucagon-like peptide (GLP)-1 agonists are a promising antidiabetic class in early-stage development that offers a novel mechanism of action. The first GLP-1 agonist likely to come to market is Amylin Pharmaceuticals' exendin-4, estimated to launch in 2005. Novo Nordisk and Novartis are also developing their own GLP-1 agonists. GLP-1 agonists exhibit multiple physiological benefits, including inducing insulin secretion in the presence of elevated glucose, delaying gastric emptying, and reducing hepatic glucose output; several different classes of drugs are currently required to achieve this range of benefits.

Type 2 Diabetes offers invaluable market intelligence for companies competing in this market. This study is part of the Immune and Inflammatory Disorders portfolio, one of six Pharmacor services that evaluate the commercial potential of drugs in research and development.

Decision Resources, Inc., is a world leader in pharmaceutical research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years. Visit the Decision Resources Web site at

Contact: Frank Sama, 781.296.2553 (telephone), 781.296.2550 (fax), or .

In Europe, contact Francoise Bidart, +32.2.351.4082 (telephone), +32.2.351.2347 (fax), or

In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (telephone), +81.3.5401.2617 (fax), or



AP Archive:

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

Contact: Frank Sama of Decision Resources, Inc., +1-781-296-2553,

Substantial Market Potential Awaits TNF-Alpha Inhibitors as They Expand into Novel Indications, According to a New Decision Resources Study

View Now